Disease Focus: Solid Tumors


A PHASE 1B STUDY EVALUATING THE SAFETY AND EFFICACY OF AN ALLOGENEIC CELL THERAPY IN SUBJECTS WITH CLEAR CELL RENAL CELL CARCINOMA (ccRCC)

Autologous ARTEMIS® T Cells to Treat Refractory/Relapsed Pediatric Liver Cancer

PHASE 1, OPEN LABEL, DOSE-ESCALATION STUDY OF CRX100 IN PATIENTS WITH ADVANCED SOLID TUMORS

BioEclipse combines two approaches – an immune cell called a cytokine-induced killer (CIK) cell and a virus engineered to kill cancer cells called an oncolytic virus (OV) – to create what they call “a multi-mechanistic, targeted treatment.” They will use the patient’s own immune cells and, in the lab, combine them with the OV. The […]

Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Hematologic Malignancies and Solid Tumors

A team at Stanford University is using a molecule known as an antibody to target cancer stem cells. This antibody can recognize and bind to CD47, a protein the cancer stem cells carry on their cell surface. The cancer cells use that protein to evade the component of our immune system that routinely destroys tumors. By disabling […]

A Phase I dose escalation and expansion clinical trial of the novel first-in-class Polo-like Kinase 4 (PLK4) inhibitor, CFI-400945 in patients with advanced solid tumors

Solid tumors are the most prevalent form of cancer, and are a major cause of death worldwide.  A team at UCLA is testing a drug for the treatment of cancer that works by blocking PLK4, a protein that is important in regulating cell growth, division and death. This protein is important for the survival of […]

Stem Cell-based Disease Modeling Shared Resource Laboratory

Our Shared Resource Laboratory will expand access to stem cell-derived models to support research and educational programs with two main goals: democratize access to state-of-the-art models and technology among a diverse scientific community and catalyze innovation in regenerative medicine. This Shared Resource Laboratory will expand access to stem cell-derived models to regions of Southern California […]

Development of universal off-the-shelf iPSC derived dendritic cells for use as patient specific anti-tumor vaccine

Research Objective This proposal aims to develop a novel cell based vaccine for the treatment of cancer. The vaccine would be derived from stem cells and be personalized to the genetics of the patient and their cancer. Impact Success would provide proof-of-principle of a novel cell based therapy for cancers broadly. It is expected to […]

Developing a breast cancer stem cell drug

Research Objective To make a drug that kills breast cancer stem cells Impact Metastatic breast cancer is incurable. The goal is to make a drug leading to cures Major Proposed Activities Make a novel drug that potentially more effectively treats breast cancer with less toxicity Test the drug for efficacy and toxicity Breast cancer is […]

Reprogramming Somatic Cells into iPSCs Engineered with an Anti-PSCA CAR to Develop Allogeneic Off-the-Shelf Cell Therapy to Treat Pancreatic Cancer

Research Objective Our candidate product PSCA-CAR_s15 uiNK is derived from transduction of iPSCs selected from the most ideal source and episomally reprogrammed from mature NK cells or CD34+ cells. Impact Cell Functionality and Quality; Scale up and Manufacture Major Proposed Activities Development and characterization of induced pluripotent stem cells (iPSCs) via somatic cell reprogramming of […]

Reversal of dysregulated myelopoiesis in breast cancers and cancer stem cells to boost antitumor immunotherapy

Research Objective A new antiestrogen drug will be developed to stop breast cancer (BC) by direct effects on BC cells including stem cells and indirect action on specific procancer immune cells that surround the cancer. Impact Substantial numbers of patients with localized breast cancer (BC) and essentially all patients with advanced BC become resistant to […]

1 2 3 4 5 6 7 8 9